Critical Materials
A levered, structurally-loss-making graphite-electrode pure-play whose old take-or-pay earnings are gone, now priced as a distressed call option on a 2026 electrode-price recovery that has to clear a 2029 debt wall — own the bonds' problem, not the equity, until pricing turns or the balance sheet is fixed.
Research
The verdict
A levered, structurally-loss-making graphite-electrode pure-play whose old take-or-pay earnings are gone, now priced as a distressed call option on a 2026 electrode-price recovery that has to clear a 2029 debt wall — own the bonds' problem, not the equity, until pricing turns or the balance sheet is fixed.
GrafTech (founded 1886, incorporated Delaware, HQ Brooklyn Heights OH) is a near-pure-play manufacturer of ultra-high-power (UHP) graphite electrodes — the industrial consumable that conducts electricity to melt scrap in electric arc furnace (EAF) steelmaking. One reportable segment: Industrial Materials. Electrodes are "the only known commercially available product" with the conductivity + heat tolerance EAF steel requires, yet represent <2% of a typical EAF's total steel-production cost — an essential, low-share-of-wallet consumable. ~96% of 2025 electrode volume went to EAF steel producers; the rest into ladle furnaces, TiO₂, silicon/ferro-alloys.
The defining structural fact: GrafTech is substantially vertically integrated into petroleum needle coke via its Seadrift plant (Port Lavaca, TX) — the key raw material. Seadrift has nameplate capacity of ~140k MT of calcined needle coke, ~one-fifth of global (ex-China) production capacity. This is the single most differentiated asset in the company.
Contract structure — the heart of the story. Historically GrafTech sold the bulk of volume under 3-to-5-year take-or-pay LTAs signed at the 2018 price peak (~$9,600/MT). The substantial majority of those LTAs have now expired, shifting the mix to short-term (annual/semi-annual/quarterly) agreements and spot. The book is built mostly in Q4 each year; there is a lag between price negotiation and revenue recognition. There is no widely accepted graphite-electrode reference price — pricing is cyclical and tracks a spread over needle coke (historical avg spread ~$4,000/MT over 2006–2025, inflation-adjusted; recent spreads much narrower).
Plain terms: GrafTech makes the carbon rods every mini-mill burns through, mines its own key ingredient, and used to lock in fat multi-year prices that have now rolled off into a brutal spot market.
Mapped upstream → company → end customer, naming every link:
Single-source dependency: Seadrift is both the company's biggest strategic moat and a concentration risk — Seadrift and Calais both sit <50 ft above sea level (climate/flood exposure flagged in risk factors).
The honest read: the Seadrift moat is durable and underappreciated, but it protects cost, not price — and the equity is dying on price.
One reportable segment (Industrial Materials) — no product-level segment P&L to disaggregate; segments.csv is empty. Geography (net sales mix, 2025): ~94% EMEA + Americas, ~6% APAC; ~59% of sales outside the US (vs 68% in 2024, 67% in 2023 — i.e. a deliberate shift toward the US, the strongest-priced region). Management estimates the higher US mix added ~$135/MT to 2025 weighted-average selling price. Volume trend: sales volume 109.2k MT in 2025 (+6% YoY), production 112.3k MT (+15%) — volume is accelerating while price decelerates, the central tension of this name.
The most important slide in the book: volume up, loss wider.
| Metric (Q1) | Q1 2026 | Q1 2025 | Δ |
|---|---|---|---|
| Net sales | $125.1M | $111.8M | +12% |
| Sales volume | 28.1k MT | 24.7k MT | +14% |
| Cost of goods sold | — | — | +22% YoY |
| Net loss | $(43.3)M | $(39.4)M | worse |
| Loss per share | $(1.66) | $(1.52) | worse |
| Adjusted EBITDA | $(13.5)M | $(3.7)M | sharply worse |
| EBITDA | $(3.6)M | $(4.9)M | |
| Free cash flow | $(27.1)M | $(42.5)M | improved (working-capital timing) |
| Cash & equivalents | $120.2M | — | down from $138.4M (YE25) |
| Total stockholders' deficit | $(304.4)M | — | deepened from $(259.6)M (YE25) |
| Capacity utilization | 65% | 63% |
The damning line: COGS rose +22% on +12% revenue, so a 14%-higher-volume quarter produced a wider loss and adjusted EBITDA fell from $(3.7)M to $(13.5)M. The volume-share-gain strategy is working on volume and failing on profit. Market reaction: stock fell ~8.4% pre-market on the print; reported a wider-than-expected loss (one outlet: $(2.05) "EPS" vs $(1.42) est. — likely a non-GAAP basis; GAAP LPS was $(1.66)) while beating on revenue.
Full-year 2025 (10-K): Net sales $504.1M (−6% YoY; 2024 $538.8M, 2023 $620.5M); net loss $(219.8)M (2024 $(131.2)M, 2023 $(255.3)M); LPS $(8.45); Adjusted EBITDA $(9.1)M (2024 +$1.6M — i.e. went negative); FCF $(120.5)M; net cash used in operations $(81.6)M. Weighted-average realized price ~$4,100/MT (−13% YoY); spot ~$4,100/MT. Balance-sheet flags below (Lens 10).
Guidance/outlook: 2026 sales volume +5–10% (Q1 ~+10%), ~65% of 2026 book committed, capex ~$35M, cash COGS/MT down low-single-digit %; management concedes pricing remains "unsustainably low" into 2026.
No transcripts on the shelf (transcripts/ empty) — sourced from web call coverage. Tone arc across the last several calls: defiant-operational, not triumphant. Consistent recurring phrases: "compelling customer value proposition," "gaining market share," "shifting mix to the US," "disciplined approach of foregoing volume where margins are unacceptable," "cumulative cash-COGS/MT down 31% since end-2023." What they keep flagging and won't stop saying: pricing is "unsustainably low," competitor behavior "aggressive … arguably irrational". New on the Q1-2026 call: announced a $600–$1,200/MT price increase (effective 2026-03-26) and warned of rising decant-oil/needle-coke cost in H2 plus Middle East logistics/energy volatility. Net: management has pivoted from "wait for the cycle" to "we are actively trying to force price up" — an admission that volume alone won't fix it.
| Company | Ticker | Mkt cap | EV | EV/EBITDA | P/E | Note |
|---|---|---|---|---|---|---|
| GrafTech | EAF | ~$0.20–0.24B | ~$1.15–1.31B | NM (negative; TTM EBITDA ~$(27)M) | NM (loss) | Net debt ~$1.0B is ~83% of EV |
| HEG Ltd | HEG (NSE) | ~$1.03B | n/a | ~10x on core electrode biz (analyst SOTP) | n/a | Profitable — Q4 FY25 EBITDA margin 19.5%; owns 8.23% of GrafTech (Oct 2024) |
| Graphite India | GRAPHITE (NSE) | n/a | n/a | n/a | n/a | Indian peer |
| Resonac (ex-Showa Denko) | 4004 (TYO) | n/a | n/a | n/a | n/a | Closed Omuta JP plant late-2025; shifting to Malaysia JV |
| Tokai Carbon | 5301 (TYO) | n/a | n/a | n/a | n/a | JP peer, US presence |
Conflict flagged (do not silently resolve): some 2026 web screens still cite a GrafTech "median analyst target of $1.15" and "price $1.28" with an EV/EBITDA of −69.67. Those price levels are pre-reverse-split (1-for-10, Aug-2025); the company now trades ~$6–9. The $1.15 target ≈ ~$11.50 post-split — but I will not treat the screen-scraped $1.15 as a current target because the basis is ambiguous; the reliable, internally-consistent facts are: price ~$7.82–8.87 (Jun 9–10 2026), 52-wk range $4.92–$20.32, mkt cap ~$0.20B, and 0 Buy / 5 Hold / 0 Sell with consensus FY2026 EPS ~$(5.19). Recent rating actions: BMO raised target +$2 (May 2026); JPMorgan and RBC lowered targets (Feb 2026).
The single most useful comp line: HEG, a direct electrode peer, is profitable (19.5% EBITDA margin) and worth ~5x GrafTech's market cap on similar revenue — GrafTech's distress is company/balance-sheet specific, not purely industry-wide.
Pattern (mostly ``):
What the tape actually reacts to for EAF: (1) electrode pricing / spread direction, (2) LTA/contract structure news, (3) balance-sheet/liquidity events (refi, reverse split, equity dilution risk), (4) any China/needle-coke/battery-anode optionality headline. Earnings beats on volume don't help; the market trades the price recovery and solvency questions.
Forensic posture — this balance sheet is the whole bear case.
Regulatory findings (required sub-section).
Bottom-up from FY2025 actuals + 2026 guidance. Every line labeled; outputs ``. No forecast.ts create per --watchlist rules.
Anchors: FY25 net sales $504.1M, volume 109.2k MT, realized price ~$4,100/MT, adj. EBITDA $(9.1)M, interest $104M, D&A ~$55–62M, shares ~26.0M, capex ~$35M (2026 guide).
Revenue drivers:
Base case — modest volume (+7%), partial price capture (~+$400/MT realized net of mix, i.e. ~$4,500/MT), cash-COGS/MT down low-single-digit, decant-oil cost headwind in H2:
Bull case — full $600–$1,200/MT capture + 2026 EAF recovery (US/EU restocking), volume +10%, cost-out holds:
Bear case — price increase fails, China oversupply persists, decant-oil cost rises:
The number that matters more than EPS: cash runway vs the 2029 wall. Liquidity $328.7M (Q1-26). At a ~$(27)M/qtr FCF burn (Q1-26) that's ~3 years of runway — almost exactly to the 2029 maturities. If EBITDA inflects positive in 2026 the burn slows and the runway extends comfortably to refi; if it doesn't, they hit the wall light on cash. This is a solvency-timing bet, not an earnings bet.
Bull case. (1) Seadrift is a genuinely scarce, best-in-class, ~1/5-of-ex-China needle-coke asset with embedded option value on the synthetic-graphite battery-anode market and on US/EU China-decoupling in critical minerals — arguably worth more than the whole equity in a sane market. (2) Operating leverage is enormous off a depressed base: utilization 63%→ rising, cash-COGS/MT down 31% since end-2023; a $600–$1,200/MT price increase on ~115k MT is ~$70–140M of incremental EBITDA against a sub-$250M market cap. (3) The secular EAF tailwind is real — ~170Mt of ex-China EAF capacity expected by 2030, ~+200kt electrode demand vs ~800kt today. (4) Insider buying (CEO +212% shares) and a direct competitor (HEG) accumulating 8.23%. If price turns, this is a multi-bagger off a distressed base.
Bear case (permanent-impairment risks). (1) The balance sheet can kill it before the cycle turns — negative equity, negative interest coverage, $1.0B net debt, everything due 2029; a failed price recovery + continued ~$100M/yr cash burn forces a dilutive equity raise or a debt restructuring that wipes the equity (the market already whispers "out-of-court restructuring"). (2) Structural, not cyclical, oversupply — China electrode prices ~$1,971/MT vs GrafTech's ~$4,100; Chinese + Indian capacity expansion is permanent and "arguably irrational"; the old $9,600 LTA world is never coming back. (3) GrafTech is the high-cost, high-leverage Western incumbent — HEG/Graphite India are profitable at these prices and GrafTech is not, which means the marginal-producer pain lands here first.
Pre-mortem (18 months out, thesis broke): the $600–$1,200 price increase was only partially absorbed because Chinese exports stayed cheap and EU steel stayed weak; decant-oil costs rose, eating the cost-out; FCF stayed deeply negative; liquidity fell below ~$150M; GrafTech announced an equity raise / exchange offer at a distressed price; the stock halved again.
Are multiples too high? On current earnings, infinitely (negative EBITDA). On normalized (bull-case ~$150M EBITDA), EV ~$1.2B = ~8x — cheap if you believe normalization. The entire debate is P(normalization before the balance sheet breaks).
Contrarian view (what the market refuses to see): the market is pricing EAF as a slow-bleed equity zero, but it is mis-weighting two binary upside catalysts the consensus won't underwrite — (a) a successful electrode price increase (management is forcing it, and electrodes are <2% of customer cost, so demand is inelastic if supply discipline holds), and (b) a Seadrift monetization / strategic transaction (a needle-coke asset this scarce, inside a sub-$250M-equity shell, is an obvious carve-out or take-private target for a battery-materials or China-decoupling buyer). Either could re-rate the equity violently.
Dismantling the bull case. What breaks the money-machine: electrodes are a commodity with no reference price and no pricing power in oversupply — GrafTech doesn't set price, the marginal Chinese exporter does, and that price (~$1,971/MT) is below GrafTech's cash cost. Revenue concentration: ~94% EMEA+Americas EAF steel — a single regional steel recession (Europe is already "challenged") craters the book. Why the moat is weaker than bulls think: Seadrift insulates cost, but the bull case needs price to recover, and Seadrift does nothing for that; meanwhile the battery-anode optionality has been "coming soon" for years with no GrafTech revenue to show for it — it's a story, not a P&L line. Most dangerous competitor bulls underestimate: not China — HEG, which is profitable at these prices, owns 8.23% of EAF, and could dictate terms in any restructuring or consolidation. Worst capital allocation: the Brookfield-era leverage that loaded a cyclical commodity company with $1.1B of debt at the top — the equity holders inherited a bond-shaped risk. What must hold for today's price: a successful price increase and a 2026 EAF recovery and refinanceable credit markets in 2028–29 — three things, all outside management's control. If growth disappoints 20–30%: GrafTech doesn't have an earnings problem, it has a solvency problem, and a 20–30% revenue miss versus the recovery case means an equity raise at a distressed price — permanent dilution, not just a down year. Single scenario that permanently impairs: China holds electrode prices below Western cash cost through 2028 → GrafTech burns to the 2029 wall → debt-for-equity restructuring → equity ~zero. Plausibility: uncomfortably non-trivial — the credit market is already modeling it.
A leveraged, no-reserves bet on the U.S. uranium-independence trade dressed as an operating miner — production is real but trivial, the share count is the business model, and at ~300x sales you are paying for the spot price and the policy narrative, not the P&L.
A ~$1.1B market cap wrapped around a ~$40M-revenue, loss-making smelter — the only US vertically-integrated antimony producer, priced almost entirely on a back-end-loaded $125M federal-ramp promise from a serially-promotional CEO; own the antimony scarcity story, but the equity is a momentum/policy option, not a value asset.
The world's #1 vertically-integrated TiO2 producer is a high-quality asset trapped under an 11.1x-levered balance sheet in the worst pigment down-cycle in a decade — the equity is a leveraged call option on a 2027 cyclical recovery (plus a free rare-earth lottery ticket), not an investment, and the 2029 maturity wall is the clock.